Hematopoiesis News Volume 2.11 | Mar 22 2011

Webinar: ALDH^br Cells and Regenerative Medicine
Aldehyde Dehydrogenase bright (ALDH^br) cells have been used in preclinical models and human clinical trials in applications such as critical limb ischemia, ischemic stroke, acute liver failure and ischemic heart failure.¹ Learn more about how ALDH^br cells could be used in regenerative medicine by registering today for an exclusive webinar presented by Dr. Andrew E. Balber of Cicada Biopharmaceutical Consulting.

Join us on April 7 at: 10AM EST (ideal for Europe) | 2PM EST (ideal for Americas) | 8PM EST (ideal for Asia-Pacific)

¹ Reviewed in Balber AE. Stem Cells (in press). DOI: 10.1002/stem.613.
Dr. Balber holds equity in and is a consultant to Aldagen, Inc., a company that is developing research, diagnostic, and therapeutic products based on detecting and isolating ALDH^br cells.

 “Like” Cell Therapy News on Facebook for a chance to win an Amazon gift card!

 Follow us on Twitter! @Hema_News

Interested in recruiting talented individuals? Post your career opportunities in Hematopoiesis News at no cost. Contact us at info@connexoncreative.com

An Anticlastogenic Function for the Polycomb Group Gene Bmi1
Researchers show that transformed human cell lines as well as primitive hematopoietic cells exhibit a high frequency of spontaneous chromosome breaks upon BMI1 depletion and are hypersensitive to genotoxic agents. [Proc Natl Acad Sci U S A]

CD41 Is Developmentally Regulated and Differentially Expressed on Mouse Hematopoietic Stem Cells
Differential and temporal expression of CD41 by hematopoietic stem cells in the distinct hematopoietic territories suggests a developmental/dynamic regulation of this marker throughout development. [Blood]

CD146 Expression on Primary Non-Hematopoietic Bone Marrow Stem Cells Correlates to In Situ Localization
Findings show that the expression of CD146 differentiates between perivascular versus endosteal localization of non-hematopoietic bone marrow stem cell populations, which has apparent implications for the study of the hematopoietic environment. [Blood]

Oxygen-Regulated Expression of the Erythropoietin Gene in a Human Renal Cell Line REPC
Here scientists present the human kidney cell line REPC (for renal erythropoietin (EPO) producing cells), established from an explanted human kidney which shows EPO gene expression and release of EPO protein in an oxygen-dependent manner. [Blood]

Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors
The purpose of this study was to determine whether mTORC2 and RI-mTORC1 complexes are present in AML cells and to examine the effects of dual mTORC2/mTORC1 inhibition on primitive AML leukemic progenitors. [Clin Cancer Res]

Phosphorylation of p27^Kip1 by JAK2 Directly Links Cytokine Receptor Signaling to Cell Cycle Control
In this study, researchers describe the identification of the cyclin-dependent kinase inhibitor p27^Kip1 as a novel janus kinase 2 (JAK2) substrate. [Oncogene]

Bcl-XL Is a Dominant Antiapoptotic Protein Which Inhibits Homoharringtonine-Induced Apoptosis in Leukemia Cells
To investigate its mechanism of action, cell growth inhibition and cytotoxicity of homoharringtonine were investigated in three acute myeloid leukemia cell lines, HL-60, NB4, and U937, and in three chronic myeloid leukemia cell lines, K562, KU812, and KCL22. [Mol Pharmacol]

FLT3-Regulated Antigens as Targets for Leukemia-Reactive Cytotoxic T Lymphocytes
Investigators analyzed the regulation of leukemia-associated antigen in FMS-like tyrosine kinase 3 (FLT3)-wild-type^– and FLT3-Internal tandem duplications⁺ myeloid cells to identify potential targets for antigen-specific immunotherapy for acute myeloid leukemia patients. [Blood Cancer J]

CLINICAL RESEARCH

Cytarabine Dose for Acute Myeloid Leukemia
Scientists compared two induction regimens in patients 18 to 60 years of age (median, 49) who had newly diagnosed acute myeloid leukemia. [N Engl J Med]

Autologous Transplantation Gives Encouraging Results for Young Adults with Favorable-Risk Acute Myeloid Leukemia but Is Not Improved with Gemtuzumab Ozogamicin
Researchers report the results of a prospective, randomized Phase III trial evaluating the use of gemtuzumab ozogamicin in an intensive consolidation approach in 657 patients, ages 17 to 60 years. [Blood]

A Phase I/II Study of Imatinib Plus Reinduction Therapy for c-Kit-Positive Relapsed/Refractory Acute Myeloid Leukemia: Inhibition of Akt Activation Correlates with Complete Response
This Phase I/II study evaluated imatinib as a c-kit inhibitor combined with mitoxantrone, etoposide and cytarabine therapy for patients with primary refractory or relapsed c-kit⁺ acute myeloid leukemia. [Leukemia]

U.K. – U.S. Stem Cell Collaboration Announced
A Memorandum of Understanding between the U.K. Stem Cell Bank and the University of Massachusetts Human Stem Cell Bank and Registry was signed. [U.K. Stem Cell Bank Press Release]

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Research Technologist – Pharmaceutical Sciences (St. Jude Children’s Research Hospital)

Associate or Assistant Researcher (University of Wisconsin-Madison)

Investigator (The Children’s Hospital of Philadelphia and the University of Pennsylvania’s School of Medicine Academic)

Postdoctoral Fellow or Research Associate (City University of New York)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.